Literature DB >> 14999153

Altered Rho GTPase signaling pathways in breast cancer cells.

Peter Burbelo1, Anton Wellstein, Richard G Pestell.   

Abstract

The Rho family of GTPases have emerged as key players in regulating a diverse set of biological activities including actin organization, focal complex/adhesion assembly, cell motility, cell polarity, gene transcription and cell-cycle progression. Some Rho GTPases and their signaling components are overexpressed and/or are hyperactive in breast cancer and recent studies have shown a requirement for Rho GTPases in breast cancer cell metastasis in vivo. Herein we describe the contribution of Rho GTPase to the malignant phenotype of breast cancer cells and the role of these pathways as potential targets for breast cancer therapy. Rho GTPases promote cell-cycle progression through cyclin D1, and cyclin D1 in turn reduces cellular adhesion and promotes migration, an example of 'inside-out' signaling by cyclin D1. As cyclin D1 overexpression correlates with metastatic cancer, the 'inside-out' signaling function of cyclin D1 to promote cell migration may represent a useful new therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14999153     DOI: 10.1023/B:BREA.0000018422.02237.f9

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  41 in total

1.  Estrogen and resveratrol regulate Rac and Cdc42 signaling to the actin cytoskeleton of metastatic breast cancer cells.

Authors:  Nicolas G Azios; Lakshmi Krishnamoorthy; Micheleen Harris; Luis A Cubano; Michael Cammer; Surangani F Dharmawardhane
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

2.  Inhibition of migration and invasion of colorectal cancer cells via deletion of Rac1 with RNA interference.

Authors:  Shi-Yi Zhao; Yan Sun; Zhuo-Sheng Lai; Qing-Zhen Nan; Kang Li; Zhen-Shu Zhang
Journal:  Mol Cell Biochem       Date:  2008-11-15       Impact factor: 3.396

3.  Characterization of EHop-016, novel small molecule inhibitor of Rac GTPase.

Authors:  Brenda L Montalvo-Ortiz; Linette Castillo-Pichardo; Eliud Hernández; Tessa Humphries-Bickley; Alina De la Mota-Peynado; Luis A Cubano; Cornelis P Vlaar; Suranganie Dharmawardhane
Journal:  J Biol Chem       Date:  2012-03-01       Impact factor: 5.157

Review 4.  Gap Junctions and Wnt Signaling in the Mammary Gland: a Cross-Talk?

Authors:  Sabreen F Fostok; Mirvat El-Sibai; Marwan El-Sabban; Rabih S Talhouk
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-09-07       Impact factor: 2.673

5.  Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.

Authors:  Ines Barone; Lauren Brusco; Guowei Gu; Jennifer Selever; Amanda Beyer; Kyle R Covington; Anna Tsimelzon; Tao Wang; Susan G Hilsenbeck; Gary C Chamness; Sebastiano Andò; Suzanne A W Fuqua
Journal:  J Natl Cancer Inst       Date:  2011-03-29       Impact factor: 13.506

Review 6.  Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.

Authors:  Behzad Yeganeh; Emilia Wiechec; Sudharsana R Ande; Pawan Sharma; Adel Rezaei Moghadam; Martin Post; Darren H Freed; Mohammad Hashemi; Shahla Shojaei; Amir A Zeki; Saeid Ghavami
Journal:  Pharmacol Ther       Date:  2014-02-26       Impact factor: 12.310

7.  Pak and Rac GTPases promote oncogenic KIT-induced neoplasms.

Authors:  Holly Martin; Raghuveer Singh Mali; Peilin Ma; Anindya Chatterjee; Baskar Ramdas; Emily Sims; Veerendra Munugalavadla; Joydeep Ghosh; Ray R Mattingly; Valeria Visconte; Ramon V Tiu; Cornelis P Vlaar; Suranganie Dharmawardhane; Reuben Kapur
Journal:  J Clin Invest       Date:  2013-09-16       Impact factor: 14.808

8.  Overexpression of RhoA induces preneoplastic transformation of primary mammary epithelial cells.

Authors:  Xiangshan Zhao; Lin Lu; Nidhi Pokhriyal; Hui Ma; Lei Duan; Simon Lin; Nadereh Jafari; Hamid Band; Vimla Band
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

9.  RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer.

Authors:  Ronil A Patel; Kara D Forinash; Roberta Pireddu; Ying Sun; Nan Sun; Mathew P Martin; Ernst Schönbrunn; Nicholas J Lawrence; Saïd M Sebti
Journal:  Cancer Res       Date:  2012-07-30       Impact factor: 12.701

Review 10.  The complex pathways of Wnt 5a in cancer progression.

Authors:  Tobias Pukrop; Claudia Binder
Journal:  J Mol Med (Berl)       Date:  2007-10-19       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.